Please login to the form below
Vertex Pharma
This page shows the latest Vertex Pharma news and features for those working in and with pharma, biotech and healthcare.
Vertex’s triple combination CF therapy to become available on the NHS
NHS England has reached an agreement with Vertex for immediate access to the pharma company’s transformative triple combination therapy for cystic fibrosis (CF). ... eligible will be able to benefit from access to Vertex’s other CF drugs.
Latest news
-
Vertex continues upward trajectory with French Orkambi deal
The American pharma giant reached an agreement with the English regulatory bodies in October, for access to Orkambi and Vertex’s other CF treatments Symkevi (tezacaftor-ivacaftor) and Kalydeco (ivacaftor). ... Vertex has also submitted the triple
-
Vertex reveals promising data from first CRISPR-treated patients
beta thalassemia,” said Jeffrey Leiden (pictured left), president and chief executive officer of Vertex. ... Vertex paid CRISPR Therapeutics $105m upfront in 2015, with up to $420m in milestone payments, to tap into its gene-editing expertise.
-
Vertex, NHS England and NICE finally reach agreement for Orkambi
to treat the underlying cause of their disease,” said Ludovic Fenaux (pictured right), senior vice president, Vertex International. ... We are pleased an agreement has been reached between NHS England and Vertex that brings these medicines to patients.
-
Vertex scores FDA approval for CF triple therapy Trikafta
The approval comes only a few months after Vertex filed the triple therapy with the FDA. ... Vertex has also submitted the triple therapy to the European Medicines Agency, with a decision expected in 2020.
-
Vertex scores CF deal with Scotland, but access debate continues
This is the first agreement within the UK for access to Vertex's CF medicines, and comes following a long history of pricing disagreements, most notably between the pharma company, NHS ... The NHS in England offered £500m over five years and £1bn over
More from news
Approximately 6 fully matching, plus 48 partially matching documents found.
Latest Intelligence
-
Health trust in a COVID-19 world – a unique opportunity for pharma
There were also some high-profile reimbursement stand-offs between pharma and the NHS (eg, Vertex/Orkambi). ... to the pharma industry, which is seen as being responsible for the high price of medicines).
-
The Cystic Fibrosis Buyers’ Club
This includes overriding pharma patents – something the group is advocating in relation to three drugs – Vertex’s cystic fibrosis treatment Orkambi, Pfizer’s breast cancer treatment Ibrance and Roche’s breast ... Meticulous preparations. The
-
Vertex: a vision of treating all CF patients worldwide draws closer
Its high prices are controversial, but Vertex also embodies the best of biopharma drug development. ... The failure of Proteostasis has led analysts to upgrade forecasts for Vertex’s own franchise.
-
The Orkambi blame game
The deadlock between pharma company Vertex and NHS England over cystic fibrosis drug Orkambi was played out in a parliamentary hearing in London on 7 March, when the company’s CEO ... NHS England accusing Vertex of being an“extreme outlier” and
-
2019: CRISPR and therapeutic gene editing comes of age
The green light came after a delay of around a year caused by manufacturing issues, which allowed another candidate from CRISPR Therapeutics and Vertex Pharma - CTX001 for the rare blood disease
More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Vertex poaches new finance chief from Ironwood Pharmaceuticals
Boston-based biotech company appoints Tom Graney. Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer. ... Tom has the ideal blend of financial acumen, leadership skills,
-
BMS appoints three independent directors
Meanwhile, Matthew Emmens and Theodore Samuels also join the pharma firm's board of directors. ... Since beginning his pharmaceutical career 40 years ago, Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Frontera Group
Dreamskin Health . Eusa Pharma. Galderma . Gedeon Richter. Genzyme. Grunenthal . Leukaemia UK. ... Novartis Pharmaceuticals. Novex Pharma. Pfizer. Shire Pharmaceuticals. UCB . Vertex Pharmaceuticals.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Keytruda doubles five-year survival rate in NSCLC
- FDA approves Roche’s Actemra COVID-19 trial
PMHub
Graphite Digital
Graphite is a digital agency which partners with globally respected healthcare organisations to create powerful digital experiences....
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
